Table II.
Blood sPD-L1 and SAA1 concentration in lung cancer subgroups.
| Parameter | Adenocarcinoma (EGFRwild type) (N=46) | Adenocarcinoma (EGFR mutation positive) (N=15) | Squamouscell carcinoma (N=31) | PD-L1+ NSCLC (N=9) | SCLC (N=14) |
|---|---|---|---|---|---|
| sPD-L1 (ng/L) | 161.4 (104.9–272.7) | 134.4 (86.0–322.5) | 196.1 (98.0–317.2) | 830.3aaa,bbb,ccc (413.0–1185.0) | 147.3dd (84.4–371.7) |
| SAA1 (mg/L) | 9.3 (2.9–28.9) | 12.6 (6.7–16.2) | 23.5 (9.2–28.3) | 48.0aa,b,c (14.5–77.0) | 26.3 (7.0–38.1) |
| sPD-L1/SAA1 ratio | 18.5 (7.0–47.5) | 14.0 (6.5–37.5) | 10.0 (5.5–35.0) | 18.0 (15.0–221.0) | 5.5 (3.0–77.5) |
P – from Mann-Whitney U test; aa,aaaP< 0.01, 0.001 vs Adenocarcinoma (EGFRwt) group; b,bbbP<0.05, 0.001 vs Adenocarcinoma (EGFR+mutation) group; cccP< 0.001 vs Squamous cell carcinoma group, ddP<0.05, 0.01 vs PD-L1+ group